Papers/PMID:40221681
Are alterations needed in Silybum marianum (Silymarin) administration practices? A novel outlook and meta-analysis on randomized trials targeting liver injury.
BMC complementary medicine and therapies2025The record
1 finding · 1 compound · 1 endpoint
What it reported
How to read these marksWhat moved
1 finding
Silybum marianum — decreases alanine aminotransferase
StrongEvidence strength: strong. Randomised human trials or their synthesis, with the effect's size and interval recorded and no recorded weakness outstanding.Finding“The pooled results from the 59 arms including 3313 patients showed a significant reduction in serum ALT levels following the administration of silymarin, with SMD (95% CI): − 0.912 (− 1.177, − 0.646), prediction interval of PI (95% CI): − 0.912 (− 2.906, 1.082) and p-value of 0.000.”
Quoted verbatim from Are alterations needed in Silybum marianum (Silymarin) administration practices? A novel outlook and meta-analysis on randomized trials targeting liver injury.. - Study
- meta-analysis
- Participants
- 3,313
- Dose
- Pooled across trials, daily doses from about 140 mg to 1050 mg
- Population
- Patients with liver disease of various causes and some other conditions, pooled across randomized trials (59 arms)
Effect -0.912 standardised mean difference, 95% CI -1.177 to -0.646
Are alterations needed in Silybum marianum (Silymarin) administration practices? A novel outlook and meta-analysis on randomized trials targeting liver injury.2025PMID:40221681Permalink